Lincoln Tech Students Selected for Cummins Technician Apprenticeship Program

WEST ORANGE, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), marking 75 years in 2021 as a national leader in specialized technical training, today announced the selection of two students this fall to receive full tuition reimbursement by diesel engine manufacturer Cummins Inc. The students, both enrolled at Lincoln Tech’s Indianapolis, IN campus, are pursuing careers in Diesel and Truck Technology through a training program supported in part by Cummins equipment donations.

“Cummins has long been a valued partner and supporter of our Diesel Technology programs across the country,” says Scott Shaw, Lincoln Tech’s President and CEO.  “We’re especially grateful to them for the financial support they are providing our students, particularly at this time of uncertainty for so many families in America. Cummins’ generosity through the Tuition Assistance Program will have a profound impact on the lives of our students, and provide a tremendous start to their careers.”

In a virtual ceremony November 13, representatives from Cummins Inc. congratulated students Annika “Niki” Rasband and Charles Moran on their selection to receive full tuition reimbursement. In addition, Rasband and Moran are eligible to take part in paid internships at Cummins’ Indianapolis Sales & Service facility, and, if offered full-time employment upon completion of their training, can also receive a $2,000 toll allotment.

“Cummins is excited for the opportunity to help Ms. Rasband and Mr. Moran continue their education in the diesel technology industry,” says Kenneth Hurst, Area Manager for Cummins’ Indianapolis branch. “This investment in their training and in their future careers will be a contributing factor to their long-term success.”

To be eligible for the award, students were required to not only maintain an excellent GPA and attendance in an Associate Degree program; they were also asked to demonstrate character and a commitment to their communities by performing at least four hours of community service. “These values are reflective of a philosophy shared by both Lincoln Tech and Cummins,” says Shaw. “Both organizations are committed to supporting the communities we serve, and the communities that are so vital to our success.”

Applicants were required to submit their current transcript, resume, two letters of recommendation, and a personal essay detailing their reasons for pursuing careers in the diesel industry.

Cummins’ support of students entering the field has been ongoing, but in 2019 the organization formally launched the Youth Technician Apprenticeship Program in partnership with the Area 31 Career Center at Ben Davis high School in Indianapolis. Rasband and Moran both graduated from the Area 31 program earlier this year before enrolling at Lincoln Tech.

By 2029 nearly 250,000 diesel technicians are projected to be hired across the country, according the U.S. Department of Labor’s Bureau of Labor Statistics. More than 8,000 of those are expected to be needed in Indiana.

In 2021 Lincoln Tech will celebrate 75 years as America’s leading career training provider. Since 1946, more than half a million graduates have gone on to launch rewarding careers throughout the nation.

 

###

 

About Lincoln Educational Services Corporation

 

Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in five principal areas of study: automotive technology, health sciences, skilled trades, information technology, and hospitality services. Lincoln has provided the workforce with skilled technicians since its inception in 1946. 

Lincoln currently operates 22 campuses in 14 states under four brands: Lincoln Technical Institute, Lincoln College of Technology, and Euphoria Institute of Beauty Arts and Sciences.  Lincoln also operates Lincoln Culinary Institute in the states of Connecticut and Maryland.

For more information, visit lincolntech.edu.



Peter Tahinos
Lincoln Educational Services
[email protected]

Aqua Metals Retires Veritex Loan, Now Debt Free

Receives Additional $0.8M Insurance Payment

MCCARRAN, Nev., Dec. 15, 2020 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), which is reinventing lead recycling with its AquaRefining™ technology, announced the Company has retired its $9.0 million debt obligation with Veritex Bank, leaving Aqua Metals essentially debt free. Further, the Company has received an additional progress payment of $0.8 million from its insurance provider. Insurance payments received to date now total $23.4 million. The Company anticipates collecting additional insurance proceeds for the replacement value of its damaged assets and potential business interruption recovery proceeds.

“The retirement of our loan with Veritex Bank is yet another positive step for Aqua Metals as we have accelerated our transition to a capital light business model. With this action, our team has achieved our previously guided goal to retire the debt by year-end. Eliminating our debt significantly strengthens the balance sheet and completely removes the burden of restrictive loan covenants. In addition, this step improves the Company’s cash burn rate by eliminating $0.9 million annually in debt service payments, including $0.6 million in interest expense. We are also pleased with the continued progress made in recovering losses through our insurance collection efforts,” stated Judd Merrill, Chief Financial Officer.

About Aqua Metals

Aqua Metals, Inc. (NASDAQ: AQMS) is reinventing lead recycling with its patented AquaRefining™ technology. Unlike smelting, AquaRefining is a room temperature, water-based process that emits less pollution. The modular systems are intended to allow the Company to vastly reduce environmental impact and scale lead acid battery recycling production capacity by licensing the AquaRefining technology to partners. This could help meet the growing demand for lead to power new applications including stop/start automobile batteries which complement the vehicle’s main battery, lead acid batteries which are in electric vehicles, Internet data centers, alternative energy applications including solar, wind, and grid scale storage. Aqua Metals is based in McCarran, Nevada. To learn more, please visit www.aquametals.com.

Aqua Metals has used, and intends to continue using, its investor relations website (https://ir.aquametals.com), in addition to its Twitter, LinkedIn and YouTube accounts at https://twitter.com/AquaMetalsInc (@AquaMatalsInc), https://www.linkedin.com/company/aqua-metals-limited and https://www.youtube.com/channel/UCvxKNWcB69K0t7e337uQ8nQ respectively, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Safe Harbor

This press release contains forward-looking statements concerning Aqua Metals, Inc. Forward-looking statements include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes”, “estimates”, “potential“ and variations of such words or similar expressions that convey uncertainty of future events or outcomes, or that do not relate to historical matters. The forward-looking statements in this press release include our expectations for the sale of the land and building at our McCarran facility; the sufficiency of any sale proceeds coupled with any further insurance recovery to fund our operations and the development and completion of our V1.25 electrolyzer; the benefits of the V1.25 electrolyzer; and the future of lead acid battery recycling via traditional smelters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the risk that we may not be able to sell the land, building and non-core equipment at our McCarran facility on a timely basis, (2) the risk that we may not realize the sale proceeds we hoped for from the sale of the land, building and non-core equipment, (3) the risk that the terms of any such sale may include indemnities or other provisions that pose potential contingent liability to Aqua Metals, (4) the risk that we may not be able to complete the development of our V1.25 electrolyzer; (5) the risk that we may not realize the expected benefits from our V1.25 electrolyzer; (6) the risk that our insurance recovery from our claims relating to the November 2019 fire at our TRIC facility and proceeds from the sale of legacy assets will not be sufficient to fund our accelerated licensing strategy; (7) the risk that we may not be able to satisfactorily demonstrate to potential licensees the technical and commercial viability of our V1.25 electrolyzer and AquaRefining process; (8) the risk that licensees may refuse or be slow to adopt our AquaRefining process as an alternative to smelting in spite of the perceived benefits of AquaRefining; (9) the risk that we may not realize the expected economic benefits from any licenses we may enter into; (10) the risk that we will have to engage in additional sales of our equity securities in order to fund our future operations; (11) the risk that further funding, by any means, may not be available at all; (12) the fact that we have not generated any significant revenue to date, thus subjecting us to all of the risks inherent in an early-stage company; (13) the risk that our patents and any other patents that may be issued to it may be challenged, invalidated, or circumvented; (14) the risk that we may not be able to successfully conclude our proposed joint development agreement with Clarios or, if we do, realize the expected benefits of such agreement; (15) changes in the federal, state and foreign laws regulating the recycling of lead acid batteries; (16) our ability to protect our proprietary technology, trade secrets and know-how and (17) those other risks disclosed in the section “Risk Factors” included in our Quarterly Report on Form 10-Q filed on October 22, 2020 and subsequent SEC filings. Aqua Metals cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Contact: Glen Akselrod, Bristol Capital
(905) 326-1888, Ext. 1
[email protected]



Devo Named APN Technology Partner of the Year

Company’s Cloud-Native Data Analytics Platform is Ideal Solution for Businesses Migrating Log Analytics Workloads to AWS

CAMBRIDGE, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) — Devo Technology, the cloud-native data analytics and security company, has been named Amazon Web Services (AWS) Partner Network (APN) Technology Partner of the Year for its dedication to helping customers build, market, and sell their offerings so they can grow successful cloud businesses.

The APN Partner Awards recognize APN members who are leaders in the channel and play a key role in helping customers to drive innovation and build solutions on AWS. Winning this award recognizes Devo as an AWS Partner that excels in offering a born-in-cloud business model that embraces specialization and collaboration.

Devo, an AWS Technology Partner, helps large enterprises gain insight by enriching all their data with context to improve business and security operations. With access to Devo in AWS Marketplace, enterprises gain the ability to migrate additional workloads to the cloud while maintaining observability into their hybrid or cloud-only environment. With its multitenant, cloud-scale platform, Devo empowers businesses to operationalize their log and metric data at significantly lower TCO.

“Our relationship with AWS is invaluable in giving us unlimited scalability to meet the needs of some of the world’s largest enterprises, which generate enormous data volumes, whether it’s 30TB a day, 50TB a day, or more,” said Upesh Patel, senior vice president of corporate development at Devo. “Being recognized as APN Technology Partner of the Year validates Devo’s tireless dedication to empowering our customers with a flexible and efficient cloud-native solution that gives them visibility and real-time access to all of their log data, enabling them to drive their business forward.”

Additional benefits of procuring and leveraging Devo through AWS include global access, as well as compatibility with AWS GovCloud to address specific markets and regulations such as GDPR.

To learn more about Devo at AWS re:Invent 2020, visit the Devo event page.

About Devo

Devo, the cloud-native logging and security analytics company, empowers security and operations teams to maximize the value of all their data. Only the Devo platform delivers the powerful combination of real-time visibility, high-performance analytics, scalability, multitenancy, and low TCO crucial for monitoring and securing business operations as enterprises accelerate their shift to the cloud. Headquartered in Cambridge, Mass., Devo is backed by Insight Partners, Georgian, and Bessemer Venture Partners. Learn more at www.devo.com.

PR Contacts:  
Devo Technology  CHEN PR for Devo Technology
Shannon Todesca Jennifer Torode

[email protected]
[email protected]
+1 (781) 797-0898 (781) 672-3119



CanWel Building Materials Announces Quarterly Dividend

NOT FOR RELEASE OR DISSEMINATION INTO THE UNITED STATES

VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — CanWel Building Materials Group Ltd. (“CanWel” or “the Company”) (TSX:CWX; CWX.NT.A) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.12 per share(1), which is the Company’s forty-third consecutive quarter of paying a dividend as a corporation, which will be paid on January 15, 2021, to shareholders of record on December 31, 2020.

About CanWel

Founded in 1989, CanWel is headquartered in Vancouver, British Columbia and trades on the Toronto Stock Exchange under the symbol CWX and is Canada’s only fully integrated national distributor in the building materials and related products sector. CanWel operates: multiple treating plant and planing facilities in Canada and the United States; distribution centres coast-to-coast in all major cities and strategic locations across Canada; in the United States near Portland, Oregon, San Francisco and Los Angeles, California and in 15 locations in the State of Hawaii through its wholly owned Honsador Building Products Group. CanWel distributes a wide range of building materials, lumber, renovation and electrical products. In addition, through its CanWel Fibre division, CanWel operates a vertically integrated forest products company based in Western Canada, operating from British Columbia to Saskatchewan, also servicing the US Pacific Northwest. CanWel owns approximately 117,000 acres of private timberlands, strategic Crown licenses and tenures, log harvesting and trucking operations, several post and pole peeling facilities and two pressure-treated specialty wood production plants and a specialty saw mill.

For further information regarding CanWel please contact:

Ali Mahdavi
Investor Relations
416-962-3300
[email protected]

Certain statements in this press release may constitute “forward-looking” statements. When used in this press release, forward-looking statements often but not always, can be identified by the use of forward-looking words such as, including but not limited to, “may”, “will”, “would”, “should”, “expect”, “believe”, “plan”, “intend”, “anticipate”, “predict”, “remain”, “estimate”, “potential”, “forecast”, “budget”, “schedule”, “continue”, “could”, “might”, “project”, “targeting”, “future” and other similar terminology or the negative or inverse of such words or terminology. Forward-looking information in this news release includes, without limitation, statements with respect to: the ultimate impact (express or implied) of the novel coronavirus COVID-19 (“COVID-19”) pandemic on the Company’s operational and financial results, including but not limited to the fourth quarter and full-year 2020 results; which impact is difficult to estimate or quantify as it will depend on inter alia the duration of the contagion, the impact of government policies, and the pace of economic recovery. These forward-looking statements reflect the current expectations of CanWel’s management regarding future events and operating performance, but involve other known and unknown or unpredictable risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanWel, including but not limited, to sales, earnings, cash flow from operations, EBITDA(2) generated, dividends generated or paid by CanWel, including whether at the rate as of the date hereof or some other dividend rate in the future which may be lower than either the current rate or preceding rate discussed in the Company’s press release dated June 15, 2020, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements should therefore be construed in the light of such factors. Actual events could differ materially from those projected herein and depend on a number of factors. These factors include but are not limited to, (i) the risk that CanWel may not be able to operate the truss design and manufacturing business of Island Truss Holdings, LLC (the “Acquisition”) or integrate the Acquisition into its operations successfully, or without negative impact on its business, or without requiring spending significant or unexpected amounts of time, money or other resources thereon, or at all; may not be able to satisfy conditions to the Acquisition on the expected terms and schedule; (ii) the risk that cost savings and synergies expected to result from the Acquisition may not be fully realized or may take longer to realize than expected; (iii) the risk that the existing and acquired business from the Acquisition will not be integrated successfully or that there is an unexpected disruption from, or reaction to, the Acquisition making it more difficult to maintain relationships with customers, employees or suppliers; (iv) the risk that CanWel may not be able to operate the lumber marketing and distribution business Lignum Forest Products LLP (the “Lignum Acquisition”) or integrate the Lignum Acquisition into its operations successfully, or without negative impact on its business, or without requiring spending significant or unexpected amounts of time, money or other resources thereon, or at all; may not be able to satisfy conditions to the Lignum Acquisition on the expected terms and schedule; (v) the risk that cost savings and synergies expected to result from the Lignum Acquisition may not be fully realized or may take longer to realize than expected (vi) the risk that the existing and acquired business from the Lignum Acquisition will not be integrated successfully or that there is an unexpected disruption from, or reaction to, the Lignum Acquisition making it more difficult to maintain relationships with customers, employees or suppliers, (vii)_the risk that CanWel may not be able to operate the lumber pressure treating plant and related equipment and business formerly owned by Western Wood Treating, Inc. (the “Plant”) or integrate the Plant into its operations successfully, or without negative impact on its business, or without requiring spending significant or unexpected amounts of time, money or other resources thereon, or at all; (viii) the risk that CanWel may not be able to obtain the final permits and operational authority to operate the Plant, or on terms and conditions or at a cost satisfactory to it, or at all; (ix) the risk that the construction and completion of CanWel’s plant in Oregon (originally announced in quarter 2, 2018 (the “Oregon Plant”)) originally expected to be in Q4 2018, may not be able to be completed or operated within expected timelines or costs, or on other terms, conditions or costs satisfactory to it, or at all; (x) the risk that CanWel may not be able to obtain the final permits and operational authority to operate the Oregon Plant on the terms and conditions satisfactory to it, or at all, or at a cost satisfactory to it; (xi) the acquisition of Honsador Acquisition Corp. (“Honsador”) in quarter 3, 2017 (collectively with the Acquisition, the Lignum Acquisition, the Plant and the Oregon Plant, the “Acquisitions”) may result in significant challenges, and management of CanWel may be unable to accomplish the integration of the Acquisitions smoothly or successfully or without spending significant or unexpected amounts of time, money or other resources thereon; (xii) the risk that any inability of management to successfully integrate the operations of the businesses or combined businesses discussed above, including, but not limited to, operational, information technology, financial reporting systems or environmental matters, any of which could have a material adverse effect on the business, financial condition and results of operations of CanWel; (xiii) the risk that revenues, profits and margins of CanWel may not remain consistent with historical levels or be as expected; (xiv) the risk that competing firms which manufacture or distribute competitive product lines will aggressively defend or seek market share, or that potential customers of the Oregon Plant and existing customers or suppliers of the Plant or Honsador (some of whom are competitors of CanWel) will change, reduce or cease doing business with CanWel, in each case reducing, eliminating or reversing any potential positive economic impact on CanWel of the Acquisitions; (xv) the risk that any cost savings, synergies, increased sales, margin, profit or distributable cash resulting or expected from the Acquisitions may not be fully realized, realized at all or may take longer to realize than expected; (xvi) the risk of disruption from the introduction, implementation and/or integration of the Acquisitions making it more difficult to maintain relationships with customers, employees or suppliers; (xvii) risks related to the operation of pressure treatment facilities, including but not limited to environmental and remediation risks, labour risks, risks related to maintenance capital expenditures for manufacturing and processing facilities and risks related to capital expenditures for environmental risks; (xviii) the potential inability of CanWel to complete the formal documentation and satisfy the other conditions required to complete the Oregon Plant; and (xix) other statements other than historical facts. As indicated above, completion of the transactions described herein are subject to various conditions, including (among others) obtaining related necessary governmental operating and regulatory permits and approvals. Although CanWel believes that the expectations and the conditions reflected in such forward-looking statements are reasonable, CanWel can give no assurance that each of these conditions will be satisfied to the satisfaction of CanWel or that expectations will prove to be correct. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of additional risks and uncertainties affecting or that could affect CanWel, which could cause actual results and developments to differ materially from those described in, expressed or implied by these forward- looking statements, include, among others: regulatory and legal risk, increased debt and interest costs, general economic and business conditions, product selling and prices, product performance, consumer preferences, design and liability risk, environmental risks, remediation risks, software and software design risk, commodity price fluctuations, information systems risk, cybersecurity risks, interest rate changes, operating costs, political or economic instability in local or national markets, chemical or commodity prices, exchange rate risks for product inputs, tariffs and tax risks and general competitive conditions. Factors also include, but are not limited to, dependence on market and economic conditions, sales and margin risk, competition, information system risks, cybersecurity risks, availability of supply of products, risks associated with the introduction of new product lines, product design risk, product liability risks, environmental risks, regulatory risk, trade and tariff risks, differing law or regulations across jurisdictions, volatility of commodity prices, inventory risks, resource industry risks, resource extraction risks, risks relating to remote operations, forestry management and silviculture risks, fire, flood and natural disaster risks, customer and vendor risks, contract performance risks, acquisition and integration risks, availability of credit, credit risks, performance bond risks, litigation risks, interest rate risks, insurance risks, risks related to climate change and risks related to the impact of local, national, and international health concerns, including but not limited to the impact and / or escalation of the COVID-19 pandemic, the COVID-19 pandemic decreasing the willingness of customers to purchase products from CanWel, causing labour or product shortages for CanWel, interrupting supplies from third parties upon which CanWel relies, or resulting in governmental regulation adversely impacting CanWel’s business, directly or indirectly. A further description of these additional factors and other risks which could cause results to differ materially from those described in these forward looking statements can be found in the periodic and other reports filed by CanWel with Canadian securities commissions and available on SEDAR (http://www.sedar.com). In addition, a number of material factors or assumptions were utilized or applied in making the forward-looking statements, and may include, but are not limited to, assumptions regarding the performance of the Canadian and U.S. economies, the relative stability of or level of interest rates, exchange rates, volatility of commodity prices, availability or more limited availability of access to equity and debt capital markets to fund, at acceptable costs, CanWel’s future growth plans, the implementation and success of the integration of the Acquisitions, the ability of CanWel to refinance its debts as they mature, the Canadian and United States housing and building materials markets; the direct and indirect effect of the U.S. housing market and economy; exchange rate fluctuations between the Canadian and US dollar; retention of key personnel; CanWel’s ability to sustain its level of sales and earnings margins; CanWel’s ability to grow its business long term and to manage its growth; CanWel’s management information systems upon which it is dependent are not impaired or compromised by breaches of CanWel’s cybersecurity; CanWel’s insurance is sufficient to cover losses that may occur as a result of its operations; international trade and tariff risks, political risks, the amount of CanWel’s cash flow from operations; tax laws; and the extent of CanWel’s future acquisitions and capital spending requirements or planning as well as the general level of economic activity, in Canada and the US, and abroad, discretionary spending and unemployment levels; the effect of general economic conditions, including market demand for CanWel’s products, and prices for such products; the effect of forestry, land use, environmental and other governmental regulations; and the risk of losses from fires, floods and other natural disasters and unemployment levels. There is a risk that some or all of these assumptions may prove to be incorrect. These and other factors could cause or contribute to actual results differing materially from those contemplated by forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements or information. There are numerous risks associated with an investment in CanWel’s common shares or senior unsecured notes, which are also further described in the “Risk Factors” sections of CanWel’s annual information form dated March 31, 2020 as well as its other public filings on SEDAR. These forward-looking statements speak only as of the date of this press release. We caution that the foregoing factors that may affect future results are not exhaustive. When relying on our forward-looking statements to make decisions with respect to CanWel, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

Neither CanWel nor any of its associates or directors, officers, partners, affiliates, or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in these communications will actually occur. You are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable securities laws and legal or regulatory obligations, CanWel is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

(
1) The adjusted dividend amount was previously announced in a CanWel Building Materials Group Ltd. press release dated June 15, 2020.

(2) In the discussion, reference is made to EBITDA, which represents earnings from continuing operations before interest, including amortization of deferred financing costs, provision for income taxes, depreciation and amortization. This is not a generally accepted earnings measure under IFRS and does not have a standardized meaning under IFRS, and therefore the measure as calculated by CanWel may not be comparable to similarly-titled measures reported by other companies. EBITDA is presented as we believe it is a useful indicator of a company’s ability to meet debt service and capital expenditure requirements and because we interpret trends in EBITDA as an indicator of relative operating performance. EBITDA should not be considered by an investor as an alternative to net earnings or cash flows as determined in accordance with IFRS. For a reconciliation of EBITDA to the most directly comparable measures calculated in accordance with IFRS refer to “Reconciliation of Net Earnings to Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) and Adjusted EBITDA(3)”.

(
3
) In the discussion, reference is made to Adjusted EBITDA, which is EBITDA as defined above, before certain non-recurring or unusual items. This is not a generally accepted earnings measure under IFRS and does not have a standardized meaning under IFRS. The measure as calculated by CanWel may not be comparable to similarly-titled measures reported by other companies. Adjusted EBITDA is presented as we believe it is a useful indicator of CanWel’s ability to meet debt service and capital expenditure requirements from its regular business, before non-recurring items. Adjusted EBITDA should not be considered by an investor as an alternative to net earnings or cash flows as determined in accordance with IFRS. For a reconciliation from Adjusted EBITDA to the most directly comparable measures calculated in accordance with IFRS refer to “Reconciliation of Net Earnings to Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) and Adjusted EBITDA”.



Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001

– Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition –

WOODCLIFF LAKE, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical isotretinoin composition (U.S. Patent Application No.: 15/772,456).

Timber’s investigational therapy, TMB-001 (topical isotretinoin), is being developed for the treatment of moderate to severe subtypes of congenital ichthyosis (CI), a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. People living with CI may have limited range of motion, chronic itching, an inability to sweat normally, high risk of secondary infections, and impaired eyesight or hearing. The management of CI is a life-long endeavor, which remains largely symptomatic and commonly focused on reducing scaling and/or skin lubrication with both systemic and topical treatments. Many dermatologists are familiar with oral isotretinoin, which was originally launched as Accutane®. By formulating isotretinoin into a proprietary topical formulation, it may be possible to reduce systemic absorption, potentially allowing for chronic use over larger areas of the body. 

“We are pleased to announce that our lead product candidate will now have patent protection in addition to potential orphan drug exclusivity pending regulatory approval as we move forward with our clinical development program for this rare dermatologic condition,” said John Koconis, Chief Executive Officer of Timber. “We believe there is an opportunity to deliver a topical composition of isotretinoin that may present many advantages over the oral systemic delivery that is in use today and help patients and families affected by CI in the years ahead.”

In 2018, the FDA awarded $1.5 million to support Phase 2a and Phase 2b clinical trials evaluating TMB-001 through its Orphan Products Clinical Trials Grant program. Timber previously announced that all 11 sites across the U.S. and Australia participating in the Phase 2b CONTROL study evaluating TMB-001 are now initiated and patients with moderate to severe CI are actively enrolling. It is a randomized, double-blind, vehicle-controlled study to investigate the safety and efficacy of two concentrations of TMB-001. 

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company’s investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, contact:

Timber Pharmaceuticals, Inc. 
John Koconis 
Chief Executive Officer
[email protected]

Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
[email protected]

Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
[email protected]



AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay


Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital


Proprietary SupraAntigen



TM



platform continues to accelerate development of first- and best-in class antibody therapeutics and diagnostics for neurodegenerative diseases

LAUSANNE, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the receipt of a highly competitive grant awarded by Target ALS. The grant, which was awarded in response to the organization’s call for new industry-led biomarker consortia projects, will support a world-class collaboration between AC Immune and Investigators at the Healey Center for ALS at Massachusetts General Hospital to accelerate the development of the Company’s proprietary immuno-assays to detect disease-associated forms of TAR DNA-binding protein 43 (TDP-43) in cerebrospinal fluid and blood samples.

The pathological aggregation of TDP-43 is strongly associated with motor and cognitive decline and episodic memory loss in several neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) and limbic-predominant age-related TDP-43 encephalopathy (LATE). AC Immune’s SupraAntigenTM-based detection assays for aggregation-prone forms of TDP-43 in biofluids have the potential to serve as an early-stage diagnostic that may enable the development of precision medicine approaches for these diseases as well as Alzheimer’s disease (AD), where pathological aggregation of TDP-43 has emerged as an important co-pathology linked to disease severity.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “This award provides further validation for our comprehensive diagnostic and therapeutic programs targeting pathological TDP-43, which represents a key component of our broad and industry-leading pipeline. Our proprietary TDP-43 immuno-assays have shown great promise, with data highlighting their high sensitivity and large dynamic range for total and phosphorylated TDP-43. The recognition of this program has mirrored that offered to our first-in-class TDP-43 positron emission tomography (PET)-tracer, which recently received a €1.45M grant from the European Union.”

“These activities, together with the development of our anti-TDP-43 therapeutic antibody, which we expect to be the first therapeutic in its class to enter clinical trials, reinforce AC Immune’s position as a leader in developing precision medicine-based approaches towards the treatment of neurodegenerative diseases. Additional programs advancing both therapeutics and diagnostics against targets such as Tau and alpha-synuclein highlight the comprehensive nature of this approach, which is crucial given the increasing recognition that neurodegenerative diseases are driven by a complex interplay of pathologies. The effective treatment of these diseases is thus likely to require combination therapies that are informed and enabled by novel diagnostics and therapeutics able to target specific proteinopathies.”

AC Immune’s proprietary immuno-assays utilize anti-TDP-43 antibodies derived from the Company’s innovative SupraAntigenTM platform, which accelerates the discovery and development of conformation-specific antibodies to successful diagnostic and therapeutic approaches. The SupraAntigenTM platform has produced multiple antibodies that bind selectively to pathological forms of human proteins involved in neurodegenerative disease such as Tau, Abeta, TDP-43, alpha-synuclein and NLRP3-ASC. This grant will accelerate the development AC Immune’s anti-pTDP-43 immuno-assay to enable ex vivo diagnostic tests capable of identifying early stages of TDP-43 related diseases such as ALS. Such diagnostic tests may facilitate the effective treatment of these diseases.

About AC Immune SA

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company’s pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

About Target ALS

Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. We envision a world in which no one dies of ALS and play a unique role in the battle against this disease. Founded in 2013 by former New York City deputy mayor Dan Doctoroff – who lost both his father and uncle to ALS – our approach is breaking down barriers and silos that previously inhibited research results. We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry. The Target ALS Innovation Ecosystem has revolutionized the field in just seven years through collaborations that have resulted in the first potential treatments since ALS was identified in 1869.

To date, the Target ALS Innovation Ecosystem, which launched in 2013 and set the groundwork for the new Target ALS Diagnosis Initiative, has yielded 175+ research projects, 12+ therapeutic targets and five clinical trials, to date.

For further information, please contact:

Head of Investor Relations

Joshua Drumm, Ph.D.
AC Immune
Phone: +1 917 809 0814
Email: [email protected]

US Media

Katie Gallagher
LaVoie Health Science
Phone: +1 617 792 3937
Email: [email protected]

Global Head of Communications

Judith Moore
AC Immune
Phone: +41 79 826 63 82
Email: [email protected]
European Investors & Media

Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
Email: [email protected]

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

 



Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems

Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong.  This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region.

SRT-100 systems utilize Sensus’ proprietary low-energy x-ray technology known as superficial radiation therapy (SRT). China, which has more than 20% of the world’s population, approved the SRT-100 for the treatment of non-melanoma skin cancer and the prevention of scars following keloidectomy in 2014 and 2017, respectively. Sensus recently renewed its focus on international sales, including Asia, with the appointment of Benson Suen as Vice President International Sales July 2020.  

Commenting on the agreement, Julie Xue, General Manager of Ekpac Healthcare Technologies, said, “We are delighted Sensus Healthcare has selected Ekpac Healthcare as its exclusive distributor, and look forward to working hand-in-hand to sell SRT-100 systems. Ekpac has more than 100 years of history in China, and is regarded as one of the most successful enterprises to bring advanced technology and devices – along with favorable financing – into China from overseas. SRT-100 systems have numerous compelling features and benefits. With the joint efforts of our two companies, we are confident tremendous success will be achieved and significant benefits will be delivered to patients across China.”

“We are excited to have Ekpac Healthcare as our partner in China, a market where we see significant opportunity over the next few years and beyond,” said Mr. Suen. “We believe that with Ekpac’s experience and their network for medical device distribution across China, they will be successful in selling SRT-100 machines to private clinics and public hospitals.  In China and around the world, our systems offer non-invasive, highly efficacious and life-changing solutions to patients who are in need.”

About EKPAC Group

Ekpac Healthcare is part of EKPAC Group, which was founded in Sweden more than 110 years ago to import Swedish brands into China. Approximately 30 years ago Ekpac Healthcare began to focus on developing its healthcare business, and now supplies more than 150 hospitals in 17 provinces in China.  Its strength is to bridge the latest needs in China with appropriate global advanced technologies, while leveraging its global network to provide clients with third-party financing for those technologies.  For more information, please visit https://ekpac.com.hk

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy x-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases these forward-looking statements can be identified by the use of forward-looking terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and healthcare, regulatory and scientific developments, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact:


LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]



Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China

Aligns Oncocyte with one of China’s fastest growing
NGS-based cancer therapy selection companies
; China is considered to be the world’s largest early-stage lung cancer market

Exclusive agreement includes payments of up to $6M in the first year and ongoing per test fees

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has signed an exclusive agreement in China to license DetermaRx™, its proprietary test to identify high-risk, early-stage lung cancer patients who need treatment to improve their five-year survival, to Burning Rock Biotech Limited, a $2.5 billion market cap NASDAQ-listed (BNR) company. Burning Rock is one of the fastest growing and largest companies in China’s next-generation sequencing (NGS) based cancer therapy selection market.

Under the agreement, Oncocyte will receive upfront cash payments after transferring and installing DetermaRx technologies, and for a fixed number of tests performed when DetermaRx achieves inclusion in the United States National Comprehensive Cancer Network (NCCN) Guidelines. Oncocyte will also receive ongoing royalties per patient tested with DetermaRx. The transfer of the testing technology is scheduled to occur in the first quarter of 2021, and the technology installation is expected to be completed by the third quarter of 2021.

China represents the largest patient population in the world for DetermaRx. This agreement marks Oncocyte’s fifth global licensing agreement and completes the Company’s stated goal of reaching all the major world markets within the first year of launch.

DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (NSCLC) patients at high-risk of recurrence despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. The test is reimbursed by Medicare. In a 250-patient prospective cohort, test-identified, low-risk patients had a five year freedom from recurrence (FFR) rate of 94.6%; test-identified high-risk or intermediate-risk patients who were treated with adjuvant platinum chemotherapy had 96.7% five year FFR compared to 71.7% five-year disease-free survival (DFS) for high-risk patients who did not receive chemotherapy. Recurrence rate in molecular high-risk stage IA patients was 25%, compared to only 3% in molecular low-risk stage IA patients.1

“This agreement with Burning Rock accelerates the ongoing expansion of our DetermaRx test to patients and physicians outside the U.S., and exemplifies our global growth strategy,” said Ron Andrews, Chief Executive Officer and President of Oncocyte. “We believe aligning with one of the largest and fastest growing companies in China’s NGS-based cancer therapy selection market speaks to the strength of DetermaRx as a valuable treatment stratification tool to help clarify this critical treatment decision point in early stage tumors. We continue to see strong growth in all of our commercial metrics thus far in the fourth quarter, and this agreement helps us achieve our goal of completing distribution agreements for DetermaRx in all major rest-of-world markets within one year of the U.S. product launch. We are honored to partner with Burning Rock whose comprehensive portfolio of molecular tests for the oncology market allows us access to the largest eligible patient population in the world as well as China’s major cancer centers. In addition to expanding our available market, this important milestone also provides us with non-dilutive capital and an ongoing revenue stream to strengthen our growth trajectory as well as help reduce our operational cash burn.”

Yusheng Han, Founder and Chief Executive Officer of Burning Rock added, “We are excited to be entering into this agreement with Oncocyte. As the leader of NGS application in oncology in China, we are committed to providing the best diagnostic solutions to Chinese patients and oncologists. China’s stage I-IIA non-squamous NSCLC incidence is estimated at over 100,000 per annum2. We believe Oncocyte’s risk stratification test fills a clear unmet need in identifying those patients who are at high risk and may benefit from adjuvant chemotherapy, versus low risk patients who do not have to undergo unnecessary chemo treatments, in a convenient and affordable manner. Combining DetermaRx with our products for genetic testing and MRD detection (currently under R&D), we can provide a comprehensive testing strategy for oncologists to ultimately benefit Chinese early-stage NSCLC patients by improving their survival and quality of life. We look forward to expanding this much-needed and promising test to the Chinese market and continuing to collaborate with Oncocyte in the future.”

For a more complete description of the terms of the agreement, please read the Exclusive Sublicense Agreement that will be filed as an exhibit to Oncocyte’s Form 8-K on or about December 14, 2020.

About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. The Company also plans to launch monitoring tests including Therasure™-CNI MONITOR, a blood-based immune therapy monitoring test, as a research use tool in 2021. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

About Burning Rock 
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

Oncocyte Forward Looking Statements
Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the timing and success of the technology installation plan or commercial launch of DetermaRx in China, unexpected delays, unexpected expenditures, indemnities or other liabilities, or other unanticipated difficulties resulting from technology transfers, commercial plans, invalidation, termination or reduction of any licensed intellectual property rights, or infringement of third party intellectual property rights, acquisitions, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte or any distributor, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Media Contact

Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
[email protected]
____________________

1 Woodard et al., 2020 North America International Association for the Study of Lung Cancer Conference Poster

2 Shi JF et al., Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer. February 2019. See also: the NCDB database, available at https://www.facs.org/quality-programs/cancer/ncdb.



NetNumber Announces General Availability of TITAN.IUM™ InterGENerational™ Platform

Major Milestone Reached for Cloud Native TITAN.IUM Platform

Lowell, MA, Dec. 15, 2020 (GLOBE NEWSWIRE) — NetNumber today announced general availability of its TITAN.IUM™ platform, the industry’s first cloud-native InterGENerational™ core network solution designed to deliver high performance, flexible services enabling CSP’s journey to 5G cloud-based infrastructures. TITAN.IUM provides an ideal approach to realize operators’ network evolution plans to cloud-native infrastructure, leveraging the capabilities, knowledge and experience gained from the widely deployed NetNumber TITAN platform and combining them into a new core infrastructure purpose-built for the cloud. 

“5G is the future, but until the future gets here for everyone, carriers still need to support 2G, 3G, and 4G phones and services,” said Andy Hicks, Principal Analyst at GlobalData Plc.  “The TITAN.IUM converged signaling platform addresses the need for multigenerational operations that enable progressive migration from legacy technology to modern networks.”

Telecom operators across the globe have responded enthusiastically to TITAN.IUM’s InterGENerational design, bringing forward the legacy network functions of 2G/3G/4G and combining them with cloud-native and 5G signaling core capabilities. Since the announcement of TITAN.IUM in June 2020, NetNumber has followed up with several proof of concept (PoC) deployments in Tier 1 providers, delivering on cloud-native, automated lifecycle management and Continuous Integration / Continuous Deployment (CI/CD) capabilities. 

The TITAN.IUM platform’s fully automated lifecycle management encompasses installation, provisioning, auto-scaling, upgrades, analytics and CI/CD, making it easier to integrate into any operator’s network and reducing the time-to-market of 5G services.  As the many generations of networks continue to evolve and coexist, TITAN.IUM’s flexible “InterGENerational” design and “deploy anywhere” implementation using native containers, Virtual Machines (VMs) or turnkey hardware/software packages, reduces migration risks and protects existing mobile core and infrastructure investments longer.  Regardless of the deployment model, as a Cloud Network Function (CNF) or Virtual Network Function (VNF), they interoperate fully and use the same management, logging, monitoring and interactive analytics engines.

“The TITAN.IUM platform is completely new from the ground up, and the result of two years of development effort,” explained Steve Legge, NetNumber Chief Operating Officer. “5G and the demands of decentralized core network architectures require new solutions to solve real-world issues, such as low latency data replication and high throughput, that arise from increasingly complex network operations.  Additionally, 5G networks won’t operate in isolation and existing network infrastructures will be around for a very long time, so supporting all generations of signaling and compute infrstructures on the new platform is critical to our customers transition to cloud native solutions.”

 

To learn more about how TITAN.IUM fulfills CSP cloud-native strategic intent, contact [email protected].

 

A new white paper “Cloud-native CSPs need unified approach to signalling to enable 5G opportunities” is available to download – https://bit.ly/3gMA3RB

About NetNumber

NetNumber, Inc. brings 20 years of experience delivering platforms that power global telecom and enterprise networks.  Our software-based signaling-control solutions accelerate delivery of new services like Private LTE and IoT/M2M solutions across multi-gen networks, dramatically simplifying the core and reducing opex.  These solutions span a range of network types from 2G-3G-4G-5G to future G delivered on the industry’s most robust signaling platform. NetNumber Data Services are essential for global inter-carrier routing, roaming, voice and messaging. Data powers fraud detection and prevention solutions and enables enterprise B2B and B2C communications platforms.  NetNumber multi-protocol signaling firewall, fraud-detection, and robocalling solutions help secure networks against current/emerging threats.

 

InterGENerational and TITAN.IUM are trademarks of NetNumber, Inc.



Kim Gibbons
NetNumber
+1 408 398 5223
[email protected]

Kaspien Holdings Announces Third Quarter Results

Net Revenue for the Third Quarter increased 36.0% and Gross Merchandise Value increased 127%

SPOKANE VALLEY, Wash., Dec. 15, 2020 (GLOBE NEWSWIRE) — Kaspien Holdings Inc. (Nasdaq: KSPN) today reported financial results for its third quarter which ended October 31, 2020.

“Our results this quarter are a testament to the progress we continue to make toward our mission of being the ultimate online growth partner for brands. Our third quarter was highlighted by higher net revenue, higher gross margin and improved operating earnings. In addition, our Gross Merchandise Value (GMV) increased 127% year-on-year as more and more brands benefit from the portfolio of services we’ve developed. As we head into the holiday season and year end, we are well positioned to scale what we’ve built and become a global leader in the Marketplace Seller Services industry,” stated Kunal Chopra, Principal Executive Officer of Kaspien Holdings Inc.

Kaspien continues to make strong progress on our plans of establishing a strong and scalable platform foundation in 2020, facilitating our 2021 “scale” phase. We continue to focus on operational efficiencies, working capital optimization, new business development and platform scale. This is evidenced by our continued growth and momentum in top line performance, platform GMV and continued improvement in operating margins. Kaspien ended the quarter with nearly 40% of GMV from corresponding subscriptions partners, comprised of agency and software subscribers.

Third Quarter Overview

  • Net revenue increased 36.0% to $38.9 million compared to $28.6 million in the third quarter of fiscal 2019. The increase in net revenue was primarily attributable to strength on the Amazon US marketplace.
  • Gross profit for the quarter increased 43.1% to $3.9 million, or 10.0% of net revenue as compared to $2.7 million, or 9.5% of net revenue for the third quarter of 2019. The increased profit was primarily attributable to a reduction in the cost of sales on the Amazon US Platform and operational efficiencies.
  • SG&A expenses for the quarter were $4.0 million, a decline of $1.2 million as compared to the third quarter of 2019. The decline in SG&A was due to a decline of $1.1 million in parent company expenses.
  • Loss from continuing operations was $0.6 million compared to a loss from continuing operations of $2.9 million for the third quarter of fiscal 2019.
  • During the quarter, the Company recorded an income tax benefit of $3.5 million related to the reversal of liabilities related to unrecognized tax benefits related to the fye business that was sold in February 2020.
  • Net income for the quarter was $2.6 million, or $1.39 per diluted share compared to a net loss of $23.2 million, or $12.73 per diluted share, for the same period last year. Included in the results for the third quarter 2019 was a loss from the fye business of $20.1 million.
  • Adjusted EBITDA (a non-GAAP measure) was $0.3 million compared to a loss of $1.0 million for the third quarter of fiscal 2019 (see note 1).

Thirty-nine weeks ended October 31, 2020
Overview

  • Net revenue for the thirty-nine weeks ended October 31, 2020 increased 15.1% to $112.8 million, compared to $98.0 million for the same period last year. The increase in net revenue was primarily attributable to strength on the Amazon US marketplace.
  • Gross profit for the thirty-nine weeks ended October 31, 2020 increased 35.4% to $11.6 million, or 10.3% of net revenue as compared to $8.6 million, or 8.8% of net revenue for the comparable period of 2019. The increased profit was primarily attributable to a reduction in the cost of sales on the Amazon US Platform and operational efficiencies.
  • SG&A expenses for thirty-nine weeks ended October 31, 2020 were $16.4 million, a decline of $1.6 million as compared to the same period of 2019.
  • Loss from continuing operations was $7.4 million compared to $11.2 million for the thirty-nine weeks ended November 2, 2019.
  • Net loss was $3.8 million, or $2.06 per diluted share, for the thirty-nine weeks ended October 31, 2020, compared to a net loss of $39.1 million, or $21.51 per diluted share, for the same period last year.
  • Adjusted EBITDA (a non-GAAP measure) was $0.9 million compared to a loss of $2.3 million for the same period last year (see note 1).
  • Cash, cash equivalents and restricted cash as of October 31, 2020 was $7.4 million, compared to $9.2 million as of November 2, 2019.
  • Borrowings under the credit facility at the end of the third quarter were $8.5 million compared to $27.8 million at the end of the third quarter last year. As of October 31, 2020, $3.8 million was available for borrowing.
  • Inventory was $27.2 million at the end of third quarter of 2020 as compared to $22.5 million at the end of the third quarter of 2019.  
Kaspian Holdings Inc.
Condensed Consolidated Financial Results
STATEMENTS OF OPERATIONS:                    
(in thousands, except per share data)                    
  Thirteen Weeks Ended   Thirty-nine Weeks Ended
  October 31, % to November 2, % to   October 31, % to November 2, % to
    2020   Revenue   2019 Revenue     2020   Revenue   2019   Revenue
                     
Net revenue $ 38,913     $ 28,616         $ 112,799     $ 98,008    
                     
Cost of sales   35,022   90.0 %   25,896     90.5 %     101,173   89.7 %   89,424   91.2 %
Gross profit   3,891   10.0 %   2,720     9.5 %     11,626   10.3 %   8,584   8.8 %
                     
Selling, general and                    
administrative expenses   3,956   10.2 %   5,140     18.0 %     16,355   14.5 %   17,940   18.3 %
Depreciation and amortization expenses   547   1.3 %   464     1.6 %     1,554   1.4 %   1,308   1.3 %
Loss from continuing operations   (612 ) -1.6 %   (2,884 )   -10.1 %     (6,283 ) -5.6 %   (10,664 ) -10.9 %
                     
Interest expense   381   1.0 %   200     0.7 %     1,016   0.9 %   508   0.5 %
                     
Net loss from continuing operations before income tax benefit   (993 ) -2.6 %   (3,084 )   -10.8 %     (7,299 ) -6.5 %   (11,172 ) -11.4 %
                     
Income tax expense (benefit)   (3,545 ) -9.1 %   10     0.0 %     (3,545 ) -3.1 %   26   0.0 %
                     
Net income (loss) from continuing operations   2,552   6.6 %   (3,094 )   -10.8 %     (3,754 ) -3.3 %   (11,198 ) -11.4 %
                     
Net loss from fye business, net of tax     0.0 %   (20,061 )   -70.1 %       0.0 %   (27,887 ) -28.5 %
                     
Net income (loss) $ 2,552   6.6 % $ (23,155 )   -80.9 %   $ (3,754 ) -3.3 % $ (39,085 ) -39.9 %
                     
Basic income (loss) per share                    
                     
Basic income (loss) per share $ 1.40     $ (12.73 )       $ (2.06 )   $ (21.51 )  
                     
Weighted average number of                    
common shares outstanding – basic   1,825       1,819           1,823       1,817    
                     
Diluted income (loss) per common share:                    
                     
Diluted income (loss) per share $ 1.39     $ (12.73 )       $ (2.06 )   $ (21.51 )  
                     
Weighted average number of                    
common shares outstanding – diluted   1,829       1,819           1,823       1,817    
                     
                     
SELECTED BALANCE SHEET CAPTIONS:             October 31,   November 2,  
(in thousands, except store data)               2020       2019    
                     
Cash, cash equivalents, and restricted cash             $ 7,428     $ 9,162    
Merchandise inventory               27,204       22,522    
Fixed assets (net)               2,343       2,102    
Accounts payable               8,559       10,169    
Borrowings under line of credit               8,483       27,771    
Long-term debt               4,581          


Notes:

  1. Reconciliation of net loss to adjusted EBITDA:

Adjusted EBITDA is defined as net income (loss), adjusted to exclude: (i) income tax expense (benefit); (ii) loss from fye business, net of tax: (iii) interest expense; (iv) Parent company SG&A expenses and (v) depreciation expense. Our method of calculating adjusted EBITDA may differ from other issuers and accordingly, this measure may not be comparable to measures used by other issuers. We use adjusted EBITDA to evaluate our own operating performance and as an integral part of our planning process. We present adjusted EBITDA as a supplemental measure because we believe such measure is useful to investors as a reasonable indicator of operating performance. We believe this measure is a financial metric used by many investors to compare companies. This measure is not a recognized measure of financial performance under GAAP in the United States, and should not be considered as a substitute for operating earnings (losses), net earnings (loss) from continuing operations or cash flows from operating activities, as determined in accordance with GAAP.

  Thirteen Weeks Ended   Thirty-nine Weeks Ended
  October 31, November 2,   October 31, November 2,
(amounts in thousands)   2020     2019       2020     2019  
           
Net income (loss) $ 2,552   $ (23,155 )   $ (3,754 ) $ (39,085 )
Income tax expense (benefit)   (3,545 )   10       (3,545 )   26  
Loss from fye business, net of tax       20,061           27,887  
Interest expense   381     200       1,016     508  
Loss from continuing operations   (612 )   (2,884 )     (6,283 )   (10,664 )
Parent company SG&A expenses   380     1,465       5,589     7,025  
Depreciation expense   547     464       1,554     1,308  
Adjusted EBITDA $ 315   $ (955 )   $ 860   $ (2,331 )

Kaspien provides a platform of software and services to empower brands to grow their online distribution channels on digital marketplaces, such as Amazon, Walmart, eBay, among others. The Company helps brands achieve their online retail goals through its innovative and proprietary technology, tailored strategies, and mutually beneficial partnerships. Kaspien is positioning itself to be a brand’s ultimate online growth partner and is guided by seven core

principles: 

  • Partner Obsession • Results
  • Insights Driven • Ownership
  • Simplicity • Diversity and Teamwork
  • Innovation  

Kaspien, formerly Trans World Entertainment, established itself as a public company in 1986, is traded on the Nasdaq National Market under the symbol “KSPN” formerly “TWMC”.

Certain statements in this release set forth management’s intentions, plans, beliefs, expectations or predictions of the future based on current facts and analyses. Actual results may differ materially from those indicated in such statements. Additional information on factors that may affect the business and financial results of the Company can be found in filings of the Company with the Securities and Exchange Commission.



Contact


:
   

Contact



:
   
      Financial Relations Board    
Ed Sapienza     Joseph Calabrese    
Chief Financial Officer     ([email protected])    
(518) 452-1242     (212) 827-3772